Published in Histopathology on July 17, 2012
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
Prognostic biomarkers in thyroid cancer. Virchows Arch (2014) 0.95
Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration. PLoS One (2015) 0.90
New insights in risk stratification of differentiated thyroid cancer. Curr Opin Oncol (2014) 0.79
High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants. Am J Cancer Res (2015) 0.76
EWSR1 rearrangement is a frequent event in papillary thyroid carcinoma and in carcinoma of the thyroid with Ewing family tumor elements (CEFTE). Virchows Arch (2017) 0.75
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. PLoS Genet (2011) 3.65
Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation (2006) 3.44
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Frequency of TERT promoter mutations in human cancers. Nat Commun (2013) 3.13
Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol (2008) 2.47
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future. Hum Mutat (2012) 2.32
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab (2006) 2.17
Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. Am J Hum Genet (2010) 2.12
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors. Mod Pathol (2011) 2.08
C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet (2008) 2.03
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res (2010) 2.03
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol (2005) 2.01
CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res (2010) 1.97
The diversity present in 5140 human mitochondrial genomes. Am J Hum Genet (2009) 1.90
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol (2005) 1.82
Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm (2009) 1.78
Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem (2007) 1.74
Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat (2012) 1.74
The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol (2008) 1.74
Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care (2007) 1.73
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy. Nephrol Dial Transplant (2004) 1.69
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat (2011) 1.65
Left ventricular outflow tract obstruction: should cardiac screening be offered to first-degree relatives? Heart (2011) 1.63
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat (2012) 1.61
Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol (2002) 1.61
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol (2004) 1.59
Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care (2006) 1.58
Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. Radiology (2005) 1.56
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.52
The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res (2004) 1.51
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail (2012) 1.51
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Homozygous nonsense mutations in KIAA1279 are associated with malformations of the central and enteric nervous systems. Am J Hum Genet (2005) 1.47
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. J Thyroid Res (2011) 1.46
Carcinoma of the thyroid with ewing family tumor elements and favorable prognosis: report of a second case. Int J Surg Pathol (2013) 1.46
Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat (2008) 1.44
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev (2006) 1.41
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid (2007) 1.41
Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (2004) 1.39
High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J (2007) 1.38
A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. Hum Mutat (2009) 1.38
Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation (2003) 1.37
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res (2007) 1.37
Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2008) 1.36
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch (2001) 1.30
A database to support the interpretation of human mismatch repair gene variants. Hum Mutat (2008) 1.27
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.25
Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet (2006) 1.23
STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.23
Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics (2011) 1.18
Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes. Hum Mutat (2007) 1.16
Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther (2005) 1.15